Hematologic Oncology Treatment Center

At Dana-Farber, we offer many clinical trials for patients with all types of lymphoma. We invite you to view these informative videos, in which our physicians provide updates on many of these trials, as well as next steps for clinical research to improve outcomes for blood cancer patients.

Lymphoma Trials and Research Updates

• Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial, Caron Jacobson, MD, MMSC (Source: OncLive)
• Dr. Jacobson explains research presented at ASCO 2020 in the use of CAR-T therapy for follicular lymphoma and marginal zone lymphoma. Promising results from a phase-2 clinical trial called ZUMA-5 showed significant and durable clinical benefits, Caron Jacobson, MD, MMSc (Source: Dana-Farber)
• Margaret Shipp, MD, explains new research that looks at the mechanism by which PD-1 blockade works in Hodgkin lymphoma, Margaret Shipp, MD (Source: Dana-Farber)
• Dr. Jacobson on the Next Steps With Axi-Cel in R/R Indolent Non-Hodgkin Lymphoma, Caron Jacobson, MD, MMSc (Source: OncLive)
• Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma, Caron Jacobson, MD, MMSc (Source: OncLive)
• EHA 2020 | ZUMA-5: Axi-cel for R/R non-Hodgkin lymphoma, Caron Jacobson, MD, MMSc (Source: VJHemOnc)
• EHA 2020 | Umbralisib with ibrutinib in patients with R/R CLL or MCL, Matthew Davids, MD, MMSc (Source: VJHemOnc)
• EHA 2020 | Impact of immunotherapy on lymphoma, Caron Jacobson, MD, MMSc (Source: VJHemOnc)
• ASH 2019 | Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after PD-1/PD-L1 Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort, Reid Merryman, MD (Source: Dana-Farber)

CLL Trials and Research Updates

• Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL, Matthew Davids, MD, MMSc (Source: OncLive)
• Dr. Davids on Factors to Inform Treatment Selection in CLL, Matthew Davids, MD, MMSc (Source: OncLive)
• Dr. Davids on Investigational Doublets and Triplets in CLL, Matthew Davids, MD, MMSc (Source: OncLive)
• Selecting Frontline Therapy for CLL, Jennifer Brown, MD, PhD (Source: Targeted Oncology)
• The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL, Matthew Davids, MD, MMSc (Source: OncLive)
• Acalabrutinib Versus Ibrutinib for CLL, Jennifer Brown, MD, PhD (Source: Targeted Oncology)
• CLL and MCL Survival Benefit from Umbralisib Plus Ibrutinib Holds Up in 4-Year Follow-Up, Matthew Davids, MD, MMSc (Source: Targeted Oncology)
• The Role of Genomic Sequencing, Jennifer Brown, MD, PhD (Source: AJMC)
• EHA 2020 | Matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve CLL, Matthew Davids, MD, MMSc (source: VJHemOnc)
• EHA 2020 | Sequence of administration of ibrutinib with obinutuzumab in R/R CLL patients, Matthew Davids, MD, MMSc (Source: VJHemOnc)
• ASCO 2020 | Venetoclax plus dose-adjusted R-EPOCH for Richter's syndrome, Matthew Davids, MD, MMSc (Source: VJHemOnc)
• Expanding Options for Treatment of CLL Using BTK Inhibitors, Jennifer Brown, MD, PhD (Source: Targeted Oncology)
• ASH 2019 | Oral time-limited duvelisib/venetoclax in R/R CLL, Matthew Davids, MD, MMSc (Source: VJHemOnc), Jennifer Crombie, MD (Source; Dana-Farber)
• ASH 2019 | Acalabrutinib, venetoclax and obinutuzumab upfront for CLL, Matthew Davids, MD, MMSc (Source: VJHemOnc)
• ASH 2019 | Dr. Ben Lampson discusses his research on germline ATM variance in chronic lymphocytic leukemia, Benjamin Lampson, MD, PhD (Source; Dana-Farber)
• EHA 2020 | Umbralisib with ibrutinib in patients with R/R CLL or MCL, Matthew Davids, MD, MMSc (Source: VJHemOnc)